



HAL
open science

Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?

Lorenzo Guglielmetti, Damien Le Dû, Nicolas Veziris, Eric Caumes, Dhiba Marigot-Outtandy, Yazdan Yazdanpanah, Jérôme Robert, Mathilde Fréchet-Jachym

► To cite this version:

Lorenzo Guglielmetti, Damien Le Dû, Nicolas Veziris, Eric Caumes, Dhiba Marigot-Outtandy, et al.. Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?. European Respiratory Journal, 2016, 10.1183/13993003.00411-2016 . hal-01345985

HAL Id: hal-01345985

<https://hal.sorbonne-universite.fr/hal-01345985v1>

Submitted on 18 Jul 2016

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**Is bedaquiline as effective as fluoroquinolones in the treatment of MDR tuberculosis:
a retrospective analysis of a French cohort**

AUTHORS:

Lorenzo Guglielmetti,^{1,2} Damien Le Dû,¹ Nicolas Veziris,^{2,3} Eric Caumes,⁴ Dhiba Marigot-Outtandy,^{1,5} Yazdan Yazdanpanah,⁶ Jérôme Robert,^{2,3*} and Mathilde Fréchet-Jachym,^{1*}; for the MDR-TB Management Group of the French National Reference Center for Mycobacteria and the Physicians of the French MDR-TB Cohort.

AFFILIATIONS:

¹ Sanatorium, Centre Hospitalier de Bligny, F-91640, Briis-sous-Forges, France

² Sorbonne Universités, UPMC Univ Paris 06, CR7, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, CIMI, Team E13 (Bactériologie), F-75013, Paris, France

³ APHP, Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux (CNR-MyRMA), Bactériologie-Hygiène, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, F-75013, Paris, France

⁴ APHP, Service des Maladies Infectieuses et Tropicales, Hôpitaux Universitaires Pitié Salpêtrière-Charles Foix, F-75013, Paris, France

⁵ APHP, Service des Maladies Infectieuses et Tropicales, CHU Raymond Poincaré, F-92380, Garches, France

⁶ APHP, Service des Maladies Infectieuses et Tropicales, Hôpital Bichat Claude Bernard, F-75013, Paris, France

* Both senior authors contributed equally to the study

Keywords: MDR-TB, XDR-TB, TMC207, moxifloxacin, levofloxacin

Running title: Bedaquiline and fluoroquinolones for MDR-TB

Corresponding author: Jérôme Robert, MD, PhD, Laboratoire de Bactériologie-Hygiène, Faculté de Médecine Pierre et Marie Curie (UPMC Paris 6), 91 Boulevard de l'hôpital, 75634 Paris Cedex 13, France; phone: (33) 1 40 77 97 49, fax: (33) 1 45 82 75 77; e-mail: jerome.robert@psl.aphp.fr

Alternate corresponding author: Lorenzo Guglielmetti, MD, MSc, address: (same as above); phone: (33) 1 40 77 97 56; e-mail: lorenzo.guglielmetti@gmail.com

Word count: 1200

Bedaquiline (Bdq) is approved for the treatment of multidrug-resistant tuberculosis (MDR-TB). In a Phase-IIIb trial, Bdq allowed a significant reduction in time-to-culture conversion and improved outcome in MDR-TB patients [1, 2]. Preliminary reports of Bdq compassionate use have shown promising results [3–5]. However, in an early bactericidal activity (EBA) study, the association of moxifloxacin (Mfx) with PA-824 and pyrazinamide showed better activity than Bdq-based associations [7]. In addition, resistance to Fq has been associated with poorer outcome in MDR-TB before Bdq use [8]. These data reinforce the pivotal role of fluoroquinolones (Fq). Comparing Bdq to Fq in interventional studies is challenging. Indeed, the paucity of drugs available for MDR-TB treatment, and the need for combination therapy often impose using all available drugs.

In an interim analysis of a Bdq-treated MDR-TB cohort, we showed that culture conversion reached 96% with 6-month Bdq-containing treatment regimens [9]. Following these encouraging results, we sought to compare the microbiological efficacy of Bdq- and Fq-containing regimens.

A retrospective study comparing microbiological outcome in Bdq-treated and Fq-treated patients was designed using the 2006-2014 cohort of MDR-TB patients hospitalized at Bligny's Sanatorium, a French referral TB centre. The first group includes patients treated for ≥ 30 days with Bdq, and either not having received any Fq or having received Fq but harbouring *Mycobacterium tuberculosis* isolates with high-level phenotypical Fq resistance. The second group comprises patients treated for ≥ 30 days with any Fq but without Bdq, with isolates susceptible to ofloxacin (Ofx) and Mfx. All patients received any second-line injectable drug and linezolid for ≥ 30 days, and had positive sputum cultures at treatment start. All regimens were individually tailored according to the drug susceptibility test (DST) results and were started at the hospital where the diagnosis was made or at the sanatorium. All drugs

were administered under direct observation and according to international guidelines [10]. Sputum cultures were repeated every two weeks up to culture conversion, and monthly thereafter. Time-to-culture conversion was measured from treatment start to the first of two consecutive negative culture results.

DST was performed at the National Reference Centre for Mycobacteria on Löwenstein-Jensen medium by the critical proportion method [11]. Resistance to Ofx was defined as mycobacterial growth at a concentration ≥ 2 mg/l. High-level Fq resistance was defined as mycobacterial growth at a concentration ≥ 2 mg/l of Mfx.

Statistical analysis was performed with STATA (StataCorp, Texas, USA). Categorical variables were compared by using Chi-square or Fisher's exact test, and continuous variables by the Wilcoxon-Mann-Whitney test. Kaplan-Meier curves for culture conversion were estimated. The Mantel-Cox test was used to compare time-to-culture conversion between the two groups. A Cox proportional hazards model was used to estimate the association between explanatory variables and time-to-culture conversion. Variables associated in univariate analysis ($p < 0.20$) were considered for backward multivariable analysis. P-values < 0.05 were considered as significant.

Bdq was provided under the national compassionate use program, and patients received information regarding this program and the safety profile of all drugs. The Institutional Review Board of Bligny's Hospital granted ethical approval.

The cohort included 119 MDR-TB patients with a positive sputum culture at the beginning of anti-tuberculosis treatment. Among them, 86 received both linezolid and any second-line injectable drug for ≥ 30 days, and 25 Bdq-treated and 42 Fq-treated patients were finally included. The median age of the 67 patients was 33 years (interquartile range, IQR: 27-40). A majority ($n=50$; 75%) was male and foreign-born ($n= 60$; 90%). Thirty-five patients

(52%) harboured isolates susceptible to any Fq and second-line injectable drug, 16 (24%) had isolates with additional resistance to only one of this two drug classes and 16 (24%) to both. Among the 25 Bdq-treated patients, 17 (68%) never received Fq and 8 (32%) received levofloxacin (Lfx), Mfx or both successively. Among the 42 Fq-treated patients, 36 (86%) received Mfx, 4 Lfx, and 2 both successively. Compared to Fq-treated patients, Bdq-treated patients were more likely to be male (96% *versus* 62%; $p=0.001$), born in Eastern Europe (84% *versus* 33%; $p<0.001$), having received prior TB treatment (92% *versus* 55%; $p=0.002$), and to have bilateral pulmonary involvement (100% *versus* 76%; $p=0.010$). There was no difference regarding the presence of lung cavities and sputum smear status at treatment start. Three patients were HIV-positive, all in the Fq-treated group. The median number of drugs to which isolates were susceptible was 5 in the Bdq-group and 8 in the Fq-group ($p<0.001$). Bdq-treated patients were less likely to receive ethambutol (28% *versus* 59%; $p=0.022$) and ethionamide (20% *versus* 48%; $p=0.036$) but more likely to receive clofazimine (32% *versus* 5%; $p=0.004$) and carbapenem-clavulanate (48% *versus* 2%; $p<0.001$). No difference was found in the proportion of patients treated with pyrazinamide, streptomycin, cycloserine and para-aminosalicylic acid.

The 3-month culture conversion rate was higher in Fq-treated (74%) than in Bdq-treated patients (44%; $p=0.02$), while no statistical difference was found at 6 months (93% *versus* 96%, respectively). The median time-to-culture conversion was shorter for Fq-treated (60 days, IQR 35-89) than for Bdq-treated patients (98 days, IQR 70-124; $p=0.005$) (Figure).

In a multivariate proportional hazard model, variables remaining associated with faster time-to-culture conversion were absence of lung cavities [Hazard Ratio (HR) 6.60, 95% Confidence Interval (CI) 3.21-13.56, $p<0.001$], negative sputum smear at treatment start (HR: 4.73, 1.01-22.08, $p=0.048$), and female sex (HR: 3.22, 1.65-6.30, $p=0.001$). Other variables,

including the treatment group, were not significantly associated with time-to-culture conversion in the multivariate model.

Our study shows no difference in culture conversion rate between Bdq-treated and Fq-treated patients at 6 months. This is promising for Bdq-treated patients, as the 6-month end-point has been linked to successful outcome [12]. Moreover, these results are observed while the characteristics of Bdq-treated patients (bilateral pulmonary involvement, number of drug for which susceptibility was demonstrated) suggest that they are more difficult to treat than the others.

Nevertheless, time-to-culture conversion was slower in the Bdq-treated than in the Fq-treated group. This is consistent with previous EBA studies [6, 7]. However, the difference may be due to companion drugs [13]. Indeed, Bdq-treated patients were less likely to receive ethambutol and ethionamide. Of interest, in the multivariate analysis, Fq-containing regimens were not associated with faster time-to-culture conversion, while TB characteristics (absence of lung cavitations and smear-negative TB) were the most determinant factors.

Female sex was linked to faster time-to-culture conversion, but all but one female patient were in the Fq-group. Nevertheless, male sex was reported as an independent risk factor for mortality in MDR-TB [14].

In the Bdq-treated group, the achievement of culture conversion closer to the 6-month endpoint may suggest continuing Bdq after 24 weeks of treatment [10] for late converters to prevent culture reversion.

Our study is limited by its observational nature. Moreover, the fact that one third of the Bdq-patients with Mfx-resistant isolates received Fq during the treatment course may have impacted the results. However, Mfx resistance is almost constantly associated with high-level resistance to other Fq [15]. Hence, it is unlikely that Fq treatment impacted culture conversion in the Mfx-resistant Bdq-treated group.

Our study suggests that the 6-month culture conversion rate is similar with Bdq- and Fq-containing regimens. The slower time-to-culture conversion in the Bdq-treated group could be explained by patients' case-mix and difference in the background regimen. Further studies are needed to relate the difference in time-to-culture conversion to treatment outcome.

Figure

Kaplan-Meier curves of sputum time-to-culture conversion in the bedaquiline and fluoroquinolone treated patients

Acknowledgements:

Members of the MDR-TB Management Group of the French National Reference Center for Mycobacteria:

C. Andrejak, A. Aubry, C. Bernard, F. Brossier, K. Chadelat, B. Dautzenberg, B. Henry, V. Jarlier, M. Jaspard, L. Raskine, B. Rivoire.

Members of the Physicians of the French MDR-TB Cohort: name (city)

N. Amiot (Orleans), E. Aslangul (Paris-Hôtel Dieu), P. Assouline (Longjumeau), E. Bergot (Caen), J.F. Boitier (Lagny), A. Bourgarit (Paris-Saint-Louis), A.S. Carrie (Avicenne), M. Caseris (Paris-Bichat), L. Colombain (Perpignan), H. Cordel (Saint Denis), N. De Castro (Paris-Lariboisière), C. Delanoe (Paris-Bichat), V. Delcey (Paris-Lariboisière), R. De Meyer-Cristiani (Bastia), M. De Menthon (Paris-Saint-Louis), B. Duchemann (Avicenne), J. Dumoulin (Boulogne-Billancourt), C. Duval (Juvisy-sur-Orge), L.I. Escaut (Paris-Kremlin Bicêtre), H. Ferrand (Paris-Bichat), R. Flicoteaux (Paris-Bichat), P. Fraisse (Strasbourg), S. Gallien (Paris-Saint-Louis), S. Girard (Le Mans), C. Godet (Poitiers), M. Gousseff (Avicenne), D. Herman (Nevers), S. Jaureguiberry (Paris-Pitié-Salpetrière), V. Joly (Paris-Bichat), N. Lerolle (Paris-Saint-Louis), D. Liné (Soissons), J. Le Grusse (Toulouse), E. Leroy-Terquem (Meulan), A. Lopes (Paris-Lariboisière), J. Macey (Paris-Cochin), G. Mellon (Paris-Bichat), J.L. Meynard (Paris-Saint-Antoine), J.C. Mouries (Bastia), J.M. Naccache (Paris-Tenon), E. Ngwem (Créteil), G. Oliviero (Longjumeau), B. Philippe (Pontoise), C. Richaud (Paris-Necker), C. Rioux (Paris-Bichat), Z. Saakashvili (Créteil), T.A. Szwebel (Paris-Hôtel Dieu), P. Vaillant (Nancy).

The authors thank all physicians and microbiologists that provided data for the study.

Potential conflicts of interest:

NV and JR belong to a research team, which has received research grants from Janssen Pharmaceutica. MFJ received payment for lectures related to multidrug-resistant tuberculosis from Astra-Zeneca.

All other authors report no potential conflict of interests for any aspect of this work.

Funding: none

REFERENCES:

1. Pontali E, Sotgiu G, D'Ambrosio L, Centis R, Migliori GB. Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence. *Eur. Respir. J.* [Internet] 2016 [cited 2016 Mar 31]; 47: 394–402; Available from: <http://erj.ersjournals.com/content/47/2/394.long>.
2. Diacon AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, Andries K, Bakare N, De Marez T, Haxaire-Theeuwes M, Lounis N, Meyvisch P, De Paepe E, van Heeswijk RPG, Dannemann B. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. *N. Engl. J. Med.* [Internet] 2014 [cited 2016 Feb 23]; 371: 723–732 Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25140958>.
3. Tiberi S, De Lorenzo S, Centis R, Viggiani P, D'Ambrosio L, Migliori GB. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. *Eur. Respir. J.* [Internet] 2014 [cited 2016 Mar 31]; 43: 289–292; Available from: <http://erj.ersjournals.com/content/43/1/289.abstract>.
4. van Halsema C, Humphreys S, Bonington A. Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. *Eur. Respir. J.* [Internet] 2014 [cited 2016 Mar 31]; 43: 292–294; Available from: <http://erj.ersjournals.com/content/43/1/292.long>.
5. Ndjeka N, Conradie F, Schnippel K, Hughes J, Bantubani N, Ferreira H, Maartens G, Mametja D, Meintjes G, Padanilam X, Variava E, Pym A, Pillay Y. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. *Int. J. Tuberc. Lung Dis.* [Internet] 2015 [cited 2016 Jan 12]; 19: 979–985; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/26162365>.
6. Rustomjee R, Diacon AH, Allen J, Venter A, Reddy C, Patientia RF, Mthiyane TCP, De Marez T, van Heeswijk R, Kerstens R, Koul A, De Beule K, Donald PR, McNeeley DF. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. *Antimicrob. Agents Chemother.* [Internet] 2008 [cited 2016 Feb 23]; 52: 2831–2835; Available from: <http://aac.asm.org/content/52/8/2831.long>.
7. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. *Lancet (London, England)* [Internet] 2012 [cited 2016 Feb 23]; 380: 986–993; Available from: <http://www.sciencedirect.com/science/article/pii/S0140673612610800>.
8. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox H, Holtz TH, Hollm-Delgado MG, Keshavjee S, Deriemer K, Centis R, D'Ambrosio L, Lange C, Bauer M, Menzies D. Resistance to fluoroquinolones and second-line injectable drugs: impact on MDR-TB outcomes. *Eur. Respir. J. Off. J. Eur. Soc. Clin. Respir. Physiol.* [Internet] 2012 [cited 2012 Nov 30]; : 09031936.00134712 – Available from:

<http://erj.ersjournals.com/content/early/2012/10/25/09031936.00134712.abstract>.

9. Guglielmetti L, Le Dû D, Jachym M, Henry B, Martin D, Caumes E, Veziris N, Métivier N, Robert J. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. *Clin. Infect. Dis.* [Internet] 2015 [cited 2015 Dec 15]; 60: 188–194; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/25320286>.
10. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: interim policy guidance [Internet]. WHO; 2013 [cited 2016 Feb 23]. Available from: <http://www.ncbi.nlm.nih.gov/books/NBK154134/>.
11. Canetti G, Rist N, Grosset J. [Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation]. *Rev. Tuberc. Pneumol. (Paris)*. [Internet] 1963 [cited 2016 Jan 5]; 27: 217–272; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/14018284>.
12. Kurbatova E V, Cegielski JP, Lienhardt C, Akksilp R, Bayona J, Becerra MC, Caoili J, Contreras C, Dalton T, Danilovits M, Demikhova O V, Ershova J, Gammino VM, Gelmanova I, Heilig CM, Jou R, Kazenny B, Keshavjee S, Kim HJ, Kliiman K, Kvasnovsky C, Leimane V, Mitnick CD, Quelapio I, Riekstina V, Smith SE, Tupasi T, van der Walt M, Vasilyeva IA, Via LE, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. *Lancet. Respir. Med.* [Internet] 2015 [cited 2016 Feb 23]; 3: 201–209; Available from: <http://www.sciencedirect.com/science/article/pii/S2213260015000363>.
13. Migliori GB, Sotgiu G, Gandhi NR, Falzon D, Deriemer K, Centis R, Hollm-Delgado MG, Palmero D, Pérez-Guzmán C, Vargas MH, D’Ambrosio L, Spanevello A, Bauer M, Chan ED, Schaaf HS, Keshavjee S, Holtz TH, Menzies D. Drug resistance beyond XDR-TB: results from a large individual patient data meta-analysis. *Eur. Respir. J. Off. J. Eur. Soc. Clin. Respir. Physiol.* [Internet] 2012 [cited 2012 Dec 12]; : 09031936.00136312 – Available from: <http://erj.ersjournals.com/content/early/2012/10/11/09031936.00136312.abstract>.
14. Balabanova Y, Ignatyeva O, Fiebig L, Riekstina V, Danilovits M, Jaama K, Davidaviciene E, Radiulyte B, Popa CM, Nikolayevskyy V, Drobniewski F. Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference? *Thorax* [Internet] 2016 [cited 2016 Apr 11]; Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27012887>.
15. Bernard C, Veziris N, Brossier F, Sougakoff W, Jarlier V, Robert J, Aubry A. Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis. *Antimicrob. Agents Chemother.* [Internet] 2015; 59: 1519–1524; Available from: <http://aac.asm.org/content/59/3/1519.long>.